Memo inOncology SPECIAL ISSUE ESMO 2016 Congress report now available in English
The 2016 memo - inOncology SPECIAL ISSUE congress report from ESMO 2016 congress summarises the latest from the lung cancer field - available now to download for free.
- Preface
- Rare driver mutations: encouraging results in small patient populations
- SCLC: genomic alterations pave the way to targeted approaches
- No phase III benefit with selumetinib in KRAS-mutant NSCLC
- EGFR-targeted therapy: at the right time in the right patient
- Targeting angiogenesis can prolong life
- Next-generation ALK inhibitors excel after crizotinib failure
- Immune checkpoint inhibition: the picture is slowly completing itself
Full Report in English